SEC Filings

SEC Filings
Home / SEC Filings

SEC Filings

10-Q
PROTALIX BIOTHERAPEUTICS, INC. filed this Form 10-Q on 05/10/2017
Entire Document
 

 

 

PROTALIX BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
SHAREHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

(U.S. dollars in thousands, except share data)

(Unaudited)

 

           Additional         
   Common   Common   paid–in   Accumulated     
   Stock (1)   Stock   capital   deficit   Total 
   Number of
shares
    Amount 
Balance at December 31, 2015   99,800,397   $100   $194,064   $(183,291)  $10,873 
Changes during the three-month period ended March 31, 2016:                         
Share-based compensation related to stock options             327         327 
Share-based compensation related to restricted stock award   7,843         48         48 
Net loss from continuing operations                  (8,526)   (8,526)
Net loss from discontinued operations                  (72)   (72)
Balance at March 31, 2016   99,808,240    100    194,439    (191,889)   2,650 
Balance at December 31, 2016   124,134,085   $124   $202,575   $(212,656)  $(9,957)
Changes during the three-month period ended March 31, 2017:                         
Share-based compensation related to stock options             118         118 
Convertible notes conversions   923,018    1    516         517 
Net loss from continuing operations                  (59,148)   (59,148)
Balance at March 31, 2017   125,057,103    125    203,209    (271,804)   (68,470)
*Represents an amount less than $1.

 

(1)Common Stock, $0.001 par value; Authorized – as of March 31, 2017 and 2016 - 250,000,000 and 150,000,000 shares, respectively.

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

 3